Obinutuzumab (Gazyva) — Clinical FAQs

Question 1

What is Obinutuzumab FDA-approved to treat?

Accepted Answer

Obinutuzumab is FDA-approved for the following oncology indications: 1. Previously untreated chronic lymphocytic leukemia (CLL) in combination with chlorambucil (FDA approval November 2013, CLL11 trial: superior PFS and OS vs rituximab + chlorambucil in elderly/unfit CLL patients) 2. Follicular lymphoma (FL): in combination with chemotherapy followed by obinutuzumab monotherapy in previously untreated FL, and in rituximab-refractory FL (GADOLIN trial: improved PFS with obinutuzumab + bendamustine vs bendamustine alone).

Question 2

How does Obinutuzumab work (mechanism of action)?

Accepted Answer

Glycoengineered type II anti-CD20 monoclonal antibody (humanized IgG1). Key features distinguishing it from rituximab (type I): (1) Glycoengineered Fc region with afucosylated sugar chains, enhancing FcγRIII binding and greatly increasing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP); (2) Type II CD20 binding via an elbow-hinge region, leading to greater direct cell death induction and CD20 homotypic aggregation; (3) Poor complement-dependent cytotoxicity (CDC) compared to type I antibodies. Unlike rituximab, obinutuzumab induces more direct non-apoptotic lysosomal cell death and less complement activation.

Question 3

How is Obinutuzumab administered?

Accepted Answer

Obinutuzumab is administered Intravenous (IV). CLL dosing: 100 mg IV on Cycle 1 Day 1, then 900 mg IV on Cycle 1 Day 2 (or 1000 mg on Day 1 if no IRR), then 1000 mg IV on Day 8 and Day 15 of Cycle 1, then 1000 mg IV on Day 1 of Cycles 2–6 (Q28 days).

Question 4

What are the most common side effects of Obinutuzumab?

Accepted Answer

The most commonly reported side effects of Obinutuzumab (≥10% incidence) include: Infusion-related reactions (IRRs): more frequent, severe, and prolonged than rituximab, especially first dose, Neutropenia, Thrombocytopenia, Anemia, Fatigue and others (8 total). Consult your oncologist for complete prescribing information.

Question 5

Does Obinutuzumab have a black box warning?

Accepted Answer

Yes. Obinutuzumab carries FDA black box warning(s) regarding: 1. Hepatitis B virus (HBV) reactivation: Can cause fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV prior to initiating treatment; monitor HBsAg+ or anti-HBc+ patients during and after treatment; initiate antiviral prophylaxis in at-risk patients. 2. Progressive multifocal leukoencephalopathy (PML): JC virus infection can result in fatal or disabling PML.

Question 6

Is Obinutuzumab safe during pregnancy?

Accepted Answer

Obinutuzumab pregnancy safety: May cause fetal B-cell depletion; effective contraception required during treatment and for 18 months after last dose.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

obinutuzumab — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms